A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE ESCALATING DOSES OF PF-07868489 IN HEALTHY ADULT PARTICIPANTS AND REPEAT DOSES IN PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION
Latest Information Update: 23 Apr 2025
At a glance
- Drugs PF-07868489 (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Pfizer
Most Recent Events
- 20 Apr 2025 Planned End Date changed from 11 Feb 2027 to 13 Feb 2027.
- 20 Apr 2025 Planned primary completion date changed from 11 Feb 2027 to 13 Feb 2027.
- 29 Oct 2024 Planned End Date changed from 12 Jan 2027 to 11 Feb 2027.